Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. The anti-EZH2 expression has been found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma.1-4 Anti-EZH2 expression has been reported in non-small cell lung cancers and lymphoma. The EZH2 protein is usually not detected in normal breast ductal epithelium. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells, or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas.